Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167872 | 0.91 | CRHR1 (0.45) | CRHR1EGFRHTTNPSR1 | |
| SCHEMBL6172799 | 0.89 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL6174523 | 0.87 | CRHR1 (0.46) | CRHR1EGFR | |
| SCHEMBL6347154 | 0.86 | CRHR1 (0.48) | CRHR1EGFRHTTNPSR1 | |
| SCHEMBL6346265 | 0.86 | CRHR1 (0.48) | CRHR1EGFRHTTNPSR1 | |
| SCHEMBL6167828 | 0.85 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL6342774 | 0.84 | CRHR1 (0.48) | CRHR1EGFR | |
| SCHEMBL6167996 | 0.84 | CRHR1 (0.48) | CRHR1EGFR | |
| SCHEMBL6167869 | 0.83 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL6168946 | 0.81 | CRHR1 (0.46) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | claimed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | claimed |
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | CRHR1 1/4885EGFR 1626/4885KCNH2 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.